Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Operating Leases: 2019-2024

Historic Operating Leases for Cidara Therapeutics (CDTX) over the last 4 years, with Dec 2024 value amounting to $1.6 million.

  • Cidara Therapeutics' Operating Leases fell 39.99% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 39.99%. This contributed to the annual value of $1.6 million for FY2024, which is 45.90% down from last year.
  • Cidara Therapeutics' Operating Leases amounted to $1.6 million in FY2024, which was down 45.90% from $3.0 million recorded in FY2023.
  • Cidara Therapeutics' Operating Leases' 5-year high stood at $3.0 million during FY2023, with a 5-year trough of $1.3 million in FY2021.
  • Over the past 2 years, Cidara Therapeutics' median Operating Leases value was $2.3 million (recorded in 2023), while the average stood at $2.3 million.
  • Data for Cidara Therapeutics' Operating Leases shows a maximum YoY slumped of 45.90% (in 2024) over the last 5 years.
  • Cidara Therapeutics' Operating Leases (Yearly) stood at $1.3 million in 2021, then reached $3.0 million in 2023, then tumbled by 45.90% to $1.6 million in 2024.